At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 182 enrolled
Drug / intervention
Lenvatinibdrug
Likely dose
Lenvatinib 24 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
In Brief
A Phase 2 clinical trial evaluating Lenvatinib for Unresectable Stage III and Stage IV Melanoma. Completed, enrolled 182 participants across 95 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Stage III, Stage IV Melanoma
CountriesAustralia, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartAug 2010
Primary CompletionApr 2013
Study CompletionNov 2014
TodayJul 2026
First PostedJun 4, 2010
Enrollment StartAug 1, 2010
Primary CompletionApr 1, 2013
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.1 years ago
Interventions
Lenvatinibdrug
Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.